Abstract: A modular jack assembly (10) includes a number of connectors (1). Each connector includes at least one receiving cavity (24) for receive a mating connector, and a plurality of contacts (4) received in the connector. The modular jack assembly also includes an engager (3) mounted in front portions of the connectors to assemble the connectors together in side-by-side arrangement.

Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.

Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.

Abstract: This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention.

Abstract: This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

Abstract: This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

Abstract: This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention.

Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.

Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.

Abstract: A wide angle projection lens include a first lens group of negative refractive power that has at least one aspheric surface. The wide angle projection lens can output an image at a half field angle of at least 45°, where the image has substantially no distortion and requires little or no keystone correction. The wide angle projection lens can be part of an optical engine that can be implemented in rear projection or front projection display devices.

Abstract: A front projection display device includes an optical engine including an illumination system, an imaging system, and projection optics. The projection optics include a first lens group of negative refractive power that has at least one aspheric surface. The projection optics output an image at a half field angle of at least 45°, where the image has substantially no distortion. For example, when the first lens group is placed at a distance of less than 1 meter from a viewing screen, the output image has a size of about 40 inches diagonal or greater, and requires substantially no keystone correction. In other aspects, the optical engine can be implemented in a wall-mounted projection system, a multimedia system, a compact integrated monitor system, and a portable projection unit.

Abstract: This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.

Abstract: This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject.

Abstract: A front projection display device having a projection module and a docking station. The docking station has a base. Further, the docking station can include an extendable arm attached to the base. The projection module contains an optical engine. The optical engine includes an illumination system, an imaging system, and a wide-angle projection lens. The optical engine outputs an image at a half field angle of at least 45°. The projected image has substantially no distortion and requires substantially no keystone correction.

Abstract: The present invention relates to a wide-angle projection lens comprising the following components in sequential order from a screen side: (a) a first lens group of positive refractive power, the first lens group having at least one aspheric surface; (b) a second lens group of negative refractive power; and (c) a third lens group of positive refractive power. The projection lens satisfies the following three conditions: Condition (1) is where |F1/F|<4.0. Condition (2) is where |F2/F|>50. And, Condition (3) is where |F3/F|<3.5. In these conditions, F is the focal length of the wide-angle projection lens; F1 is the focal length of the first lens group; F2 is the focal length of the second lens group; and F3 is the focal length of the third lens group. The wide-angle projection lens is used in a front projection display device.

Abstract: A method for assembling a PIFA antenna (20) onto a plastic base of a handle electronic device includes forming the plastic base (30) with a number of posts (35) by a single-shot-molding process and punching a number of pinholes (215) on the PIFA antenna body corresponding to the posts protruding thereon. The plastic base and the antenna body are conjoined together with the posts aligned with the pinholes. Then the posts are heated and then transfigured to flat-shape for engaging the edges of the pinholes. Thus the PIFA antenna is firmly retained on the plastic base.

Abstract: A method for assembling a PIFA antenna (20) onto a plastic base of a handle electronic device includes forming the plastic base (30) with a number of posts (35) by a single-shot-molding process and punching a number of pinholes (215) on the PIFA antenna body corresponding to the posts protruding thereon. The plastic base and the antenna body are conjoined together with the posts aligned with the pinholes. Then the posts are heated and then transfigured to flat-shape for engaging the edges of the pinholes. Thus the PIFA antenna is firmly retained on the plastic base.

Abstract: A modular jack assembly (10) includes a number of connectors (1). Each connector includes at least one receiving cavity (24) for receive a mating connector, and a plurality of contacts (4) received in the connector. The modular jack assembly also includes an engager (3) mounted in front portions of the connectors to assemble the connectors together in side-by-side arrangement.

Abstract: A method for transmitting the time-critical data over Ethernet. The method can tolerate at least 50% of packet-drop without affecting the quality of transmission. Ethernet network is considered a connectionless network, so the packet-drop is not avoidable. Therefore, the key to transmitting the time-critical data over Ethernet is not to prevent the packet-drop, but to control and to tolerate the packet-drop. To tolerate the packet-drop, we have to carry redundant data in each Ethernet packet so that we can recover the lost information from the redundant data when packet-drop occurs. An easy way of carrying the redundant data is as follows. Every packet carries two parts of data. The first part is the required data, and the second part is the redundant data. The required data is the data that the packet is supposed to carry in the case without redundant data. The redundant data is the required data of the next packet.